Delayed-start analyses in the phase 3 solanezumab expedition3 study in mild alzheimer’s disease

Objective A delayed-start design has been proposed to assess a potential disease-modifying effect in investigational drugs for Alzheimer’s disease that target the underlying disease process. We extended this methodology to recently obtained data from the EXPEDITION3.